Gen1E Lifesciences Inc., of Palo Alto, Calif., said it entered an exclusive option agreement with the University of Maryland, Baltimore to license patent rights, titled "MUC1 Decoy Peptides for Treatment and Prevention of Bacterial Infections." Terms were not disclosed.